RAPID DETECTION OF MULTI DRUG RESISTANCE AMONG MULTI DRUG RESISTANT TUBERCULOSIS SUSPECTS USING LINE PROBE ASSAY
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i1.14341Abstract
Objective: GenoType MTBDRplus line probe assay (LPA) is developed for performing drug susceptibility testing (DST) for Rifampicin (RIF) and isoniazid in sputum specimens from smear-positive pulmonary tuberculosis (TB) patients and revised national TB control Programme (RNTCP) has endorsed LPA for the diagnosis of multi drug resistant TB (MDR-TB). This study was conducted to assess the potential utility of LPA for MDR-TB patient management.
Methods: MDR-TB suspects under RNTCP PMDT criteria C referred from different districts in Delhi state were included in the study January 2013 to
December 2014. Sputum specimens found acid-fast bacilli positive by fluorescent microscopy were processed for LPA.
Results: Out of 3062 specimens, 2055 (67.1%) MDR-TB suspects were read as positive and specimens from 1007 (32.9%) suspects were read as negative in sputum smear microscopy. Out of 2019 specimens valid LPA results, 1427 were found to be pan-sensitive, 280 were MDR-TB, 40 were RIF monoresistant, 183 were Isoniazid (INH) monoresistant, and 89 specimens were found negative for Mycobacterium tuberculosis.
Conclusion: Routine use of LPA can substantially reduce the time to diagnosis of RIF and/or INH-resistant TB and can hence potentially enable earlier commencement of appropriate drug therapy and thereby facilitate prevention of further transmission of drug resistant strains.
Keywords: Multi drug resistant tuberculosis, Line probe assay, Rifampicin, Isoniazid.
Downloads
References
Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006;6(11):710-25.
World Health Organization. The Global MDR TB and XDR TB Response Plan, 2007-2008. WHO/HTM/TB/2007, 387. Geneva: World Health Organization; 2007.
Abebe G, Paasch F, Apers L, Rigouts L, Colebunders R. Tuberculosis drug resistance testing by molecular methods: Opportunities and challenges in resource limited settings. J Microbiol Methods 2011;84(2):155-60.
World Health Organization. Policy Statement. Molecular Line Probe Assays for Rapid Screening of Patients at Risk of Multidrug Resistant Tuberculosis (MDR-TB), 2008. Available from: http://www.who.int/tb/ dots/laboratory/lpa_policy.pdf. [Last accessed on 2009 Nov 18].
World Health Organization. WHO Laboratory Services in Tuberculosis Control. Part II: Microscopy. WHO/TB/98, 258. Geneva, Switzerland: WHO; 1998.
Master RN. Mycobacteriology. In: Isenburg HD, editor. Clinical Microbiology Procedures Handbook. Section 3. Washington, DC: American Society for Microbiology; 1992. p. 1.
HainLifescience. Genotype® MTBDRplus product insert. Version 1.Available from: http://www.hainlifescience.de/en/products/microbiology/mycobacteria/genotypemtbdrplus.
Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: A meta-analysis. Eur Respir J 2008;32(5):1165-74.
Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341(8846):647-50.
Van Rie A, Warren R, Mshanga I, Jordaan AM, van der Spuy GD, Richardson M, et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high- incidence community. J Clin Microbiol 2001;39(5):636-41.
Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. high prevalence of KatG ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002;46(5):1417-24.
Dorman SE, Chihota VN, Lewis JJ, van der Meulen M, Mathema B, Beylis N, et al. Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa. J Clin Microbiol 2012;50(4):1189-94.
Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high- volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177(7):787-92.
Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis. BMC Infect Dis 2005;5:62.
World Health Organization. New Laboratory Diagnostic Tools for Tuberculosis Control. Stop TB Partnership: Retooling Task Force and the New Diagnostics Working Group. Geneva, Switzerland: World Health Organization; 2008.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
